<DOC>
	<DOCNO>NCT02125877</DOCNO>
	<brief_summary>Assessed new film-coated tablet formulation currently approve dispersible tablet formulation regard overall safety , Gastrointestinal ( GI ) tolerability , palatability , satisfaction compliance</brief_summary>
	<brief_title>Phase II Study Investigate Benefits Improved Deferasirox Formulation ( Film-coated Tablet )</brief_title>
	<detailed_description />
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>Key Male female patient age ≥ 10 year Patients transfusiondependent thalassemia iron overload , require deferasirox DT dose ≥ 30 mg/kg/day per investigator 's decision OR Patients low , low intermediate ( int ) risk myelodysplastic syndrome ( MDS ) iron overload , require deferasirox DT dose ≥ 20 mg/kg/day per investigator 's decision . History transfusion least 20 PRBC unit anticipate transfused least 8 unit PRBCs annually study Serum ferritin &gt; 1000 ng/mL , measure screen Visit 1 screen Visit 2 ( mean value use eligibility criterion ) . Key Creatinine clearance contraindication limit locally approve prescribing information . Creatinine clearance estimate serum creatinine screen Visit 1 screen Visit 2 mean value use eligibility criterion . Serum creatinine &gt; 1.5 xULN screening measure screen Visit 1 screen Visit 2 ( mean value use eligibility criterion ) . ALT ( SGPT ) &gt; 5xULN , unless LIC confirm &gt; 10 mg Fe/dw within 6 month prior screen visit 1 . Significant proteinuria indicate urinary protein/creatinine ratio &gt; 0.5 mg/mg nonfirst void urine sample screen Visit 1 screen Visit 2 . Patients significant impaired gastrointestinal ( GI ) function GI disease may significantly alter absorption oral deferasirox ( e.g . ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection ) . Liver disease severity ChildPugh Class B C</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Iron overload</keyword>
	<keyword>Chelation</keyword>
	<keyword>Thalassemia</keyword>
	<keyword>Myelodysplastic syndrome ( MDS )</keyword>
	<keyword>Transfusional hemisiderosis</keyword>
	<keyword>Deferasirox</keyword>
	<keyword>ICL670</keyword>
	<keyword>Dispersible tablet</keyword>
	<keyword>Film-coated tablet</keyword>
</DOC>